Brookline Capital Markets Weighs in on MRKR Q1 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Stock analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for shares of Marker Therapeutics in a report issued on Wednesday, March 18th. Brookline Capital Markets analyst L. Cann forecasts that the company will post earnings per share of ($0.19) for the quarter. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.64) EPS and FY2026 earnings at ($1.53) EPS.

Other equities analysts have also recently issued research reports about the stock. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Zacks Research cut shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. Finally, HC Wainwright started coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They set a “buy” rating and a $10.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR opened at $1.34 on Monday. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.07. The business has a fifty day moving average price of $1.59 and a 200-day moving average price of $1.30. The company has a market capitalization of $22.34 million, a PE ratio of -1.58 and a beta of 1.42.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.17. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%.The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.68 million.

Institutional Trading of Marker Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC bought a new stake in shares of Marker Therapeutics in the fourth quarter worth approximately $222,000. Geode Capital Management LLC lifted its position in Marker Therapeutics by 35.3% during the fourth quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after purchasing an additional 34,028 shares during the period. Renaissance Technologies LLC boosted its holdings in Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares during the last quarter. Finally, LPL Financial LLC grew its position in Marker Therapeutics by 41.7% in the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares during the period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

More Marker Therapeutics News

Here are the key news stories impacting Marker Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $10.00 price target while publishing detailed quarterly and long‑term EPS model updates — a high-profile analyst backing that can attract buyers and liquidity. HC Wainwright research (via MarketBeat)
• Positive Sentiment: Brookline Cap M boosted its FY2026 EPS forecast for MRKR (revising the year loss from roughly ($2.74) to ($1.53)), signaling expectations for a smaller-than-previously-forecast cash burn or improved near‑term operating performance. Brookline Cap M note (via MarketBeat)
• Neutral Sentiment: HC Wainwright published quarterly EPS forecasts for 2027 (Q1: ($0.33), Q2: ($0.36), Q3: ($0.38), Q4: ($0.30)) and a FY2030 EPS view of ($0.75) — useful modeling inputs but they still project ongoing losses for several years. HC Wainwright forecasts (via MarketBeat)
• Neutral Sentiment: Aggregator coverage summarized analyst Q2 forecasts for MRKR; these consensus/estimates pieces are informational and help set expectations ahead of upcoming reports. Equities Analysts Issue Forecasts for MRKR Q2 Earnings
• Negative Sentiment: Consensus still forecasts a full‑year loss (approx. ($0.65) EPS), and quarter-by-quarter models remain negative — continued losses and negative margins could limit valuation multiple expansion and keep the stock volatile. Consensus estimates (via MarketBeat)
• Negative Sentiment: Historical metrics show large negative margins and negative ROE (company remains unprofitable), meaning any deterioration in operating results or funding concerns would weigh on the share price. Company fundamentals (via MarketBeat)

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.